skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma

Abstract

Purpose: To evaluate treatment results of stereotactic radiosurgery or fractionated stereotactic radiation therapy (SRS/FSRT) for uveal melanoma. Methods and Materials: We retrospectively evaluated 181 patients with 182 uveal melanomas receiving SRS/FSRT between 2007 and 2013. Treatment was administered with CyberKnife. Results: According to Collaborative Ocular Melanoma Study criteria, tumor size was small in 1%, medium in 49.5%, and large in 49.5% of the patients. Seventy-one tumors received <45 Gy, and 111 received ≥45 Gy. Median follow-up time was 24 months. Complete and partial response was observed in 8 and 104 eyes, respectively. The rate of 5-year overall survival was 98%, disease-free survival 57%, local recurrence-free survival 73%, distant metastasis-free survival 69%, and enucleation-free survival 73%. There was a significant correlation between tumor size and disease-free survival, SRS/FSRT dose and enucleation-free survival; and both were prognostic for local recurrence-free survival. Enucleation was performed in 41 eyes owing to progression in 26 and complications in 11. Conclusions: The radiation therapy dose is of great importance for local control and eye retention; the best treatment outcome was achieved using ≥45 Gy in 3 fractions.

Authors:
 [1];  [2]; ; ;  [1];  [3];  [4];  [1]
  1. Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara (Turkey)
  2. Department of Ophthalmology, Faculty of Medicine, Hacettepe University, Ankara (Turkey)
  3. Bascom Palmer Eye Institute, Miami, Florida (United States)
  4. Department of Radiology, Faculty of Medicine, Hacettepe University, Ankara (Turkey)
Publication Date:
OSTI Identifier:
22649918
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 98; Journal Issue: 1; Other Information: Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; EYES; GY RANGE 10-100; MELANOMAS; RADIATION DOSES; RADIOTHERAPY; SURGERY

Citation Formats

Yazici, Gozde, Kiratli, Hayyam, Ozyigit, Gokhan, Sari, Sezin Yuce, Cengiz, Mustafa, Tarlan, Bercin, Mocan, Burce Ozgen, and Zorlu, Faruk, E-mail: fzorlu@hacettepe.edu.tr. Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma. United States: N. p., 2017. Web. doi:10.1016/J.IJROBP.2017.02.017.
Yazici, Gozde, Kiratli, Hayyam, Ozyigit, Gokhan, Sari, Sezin Yuce, Cengiz, Mustafa, Tarlan, Bercin, Mocan, Burce Ozgen, & Zorlu, Faruk, E-mail: fzorlu@hacettepe.edu.tr. Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma. United States. doi:10.1016/J.IJROBP.2017.02.017.
Yazici, Gozde, Kiratli, Hayyam, Ozyigit, Gokhan, Sari, Sezin Yuce, Cengiz, Mustafa, Tarlan, Bercin, Mocan, Burce Ozgen, and Zorlu, Faruk, E-mail: fzorlu@hacettepe.edu.tr. Mon . "Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma". United States. doi:10.1016/J.IJROBP.2017.02.017.
@article{osti_22649918,
title = {Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma},
author = {Yazici, Gozde and Kiratli, Hayyam and Ozyigit, Gokhan and Sari, Sezin Yuce and Cengiz, Mustafa and Tarlan, Bercin and Mocan, Burce Ozgen and Zorlu, Faruk, E-mail: fzorlu@hacettepe.edu.tr},
abstractNote = {Purpose: To evaluate treatment results of stereotactic radiosurgery or fractionated stereotactic radiation therapy (SRS/FSRT) for uveal melanoma. Methods and Materials: We retrospectively evaluated 181 patients with 182 uveal melanomas receiving SRS/FSRT between 2007 and 2013. Treatment was administered with CyberKnife. Results: According to Collaborative Ocular Melanoma Study criteria, tumor size was small in 1%, medium in 49.5%, and large in 49.5% of the patients. Seventy-one tumors received <45 Gy, and 111 received ≥45 Gy. Median follow-up time was 24 months. Complete and partial response was observed in 8 and 104 eyes, respectively. The rate of 5-year overall survival was 98%, disease-free survival 57%, local recurrence-free survival 73%, distant metastasis-free survival 69%, and enucleation-free survival 73%. There was a significant correlation between tumor size and disease-free survival, SRS/FSRT dose and enucleation-free survival; and both were prognostic for local recurrence-free survival. Enucleation was performed in 41 eyes owing to progression in 26 and complications in 11. Conclusions: The radiation therapy dose is of great importance for local control and eye retention; the best treatment outcome was achieved using ≥45 Gy in 3 fractions.},
doi = {10.1016/J.IJROBP.2017.02.017},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 1,
volume = 98,
place = {United States},
year = {Mon May 01 00:00:00 EDT 2017},
month = {Mon May 01 00:00:00 EDT 2017}
}